London, UK (PRWEB) June 18, 2014
Owing to the poor prognosis under presently available treatment options, therapies with high potency are in strong demand in the world glioblastoma multiforme (GBM) market. In newly diagnosed patients, the present standard of care, encompassing radiation therapy, resection surgery and chemotherapy with Merck’s Temodar, has a maximum overall survival (OS) of fifteen months and almost inevitable tumor recurrence. Presently available therapeutic options for recurrent GBM are carmustine, Roche’s Avastin (bevacizumab) and some other chemotherapy drugs used in off-label ways. However, these therapies merely provide limited OS benefit, thus leaving high unmet need in this patient pool.
In 2012, the global GBM market stood at around USD 305 million. In 2019, the world GBM market is anticipated to grow rapidly and amount to USD 583 million. The growth in the market will considerably be driven by the entry of Northwest Biotherapeutics’ DCVax-L to the market. Having shown higher OS improvement in comparison with the standard treatment alone in clinical trials, it is anticipated to bear high market potential, because its efficacy is translated into larger Phase III trials. The targeted therapy Cotara and the cancer vaccine Rindopepimut (CDX-110) are also expected to enter the world GBM market, but will stimulate the growth in the overall market to a lesser extent than Northwest Biotherapeutics’ DCVax-L.
New research report “Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany” elaborated by GBI Research is now available at MarketPublishers.com.
Title: Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
Published: June, 2014
Price: US$ 3,500.00
The report presents an all-round overview of the world GBM therapeutics market and also provides a comprehensive analysis of the developmental pipeline for GBM (including detailed analysis of a range of late-stage pipeline drugs that are expected to enter the market in the years ahead). Besides, the study contains a brief profile for GBM encompassing details on the disease pathogenesis, diagnosis and risk factors; offers an insightful review of the currently available drugs with information on their efficacy, safety, treatment patterns and also weaknesses and strengths. The report gives an in-depth assessment of GBM clinical trials by molecule type, phase, trial duration and size and program failure rate; uncovers multi-scenario market data for the world GBM therapeutics market with a close look at the major developed markets for GBM therapeutics, namely Germany, Canada, the US, the UK, Italy, Japan, Spain and France. The topical study examines the major drivers and limiters of the market growth, touches upon the co-development and licensing deals landscape, presents insights into the competitive scenario and, moreover, outlines future growth prospects for the world GBM therapeutics market through 2019 with detailed forecast for the major developed markets.
Reasons to Buy:
- Gain a comprehensive understanding of the various levels of GBM therapies for newly diagnosed as well as recurrent GBM.
- Get a clear idea of the vast scope of the GBM therapeutic pipeline.
- Determine the most prominent molecule types and mechanisms of action.
- Become abreast of the top trends in clinical trial size and duration by clinical phase and molecule type.
- Be able to assess the risk profiles of the present and/or future developmental programs for GBM therapeutics.
- Evaluate the potential commercial and clinical impact of the actual late-stage pipeline molecules on the world GBM therapeutics market.
- Compare the current scenario in the major developed markets for GBM therapeutics.
- Find out how the global GBM therapeutics market is set to develop through 2019.
More new market research reports by the publisher can be found at GBI Research page.